DHT blocker, no
In vitro studies allow for precise control over dosage, but animal studies require adjustments to account for factors like body weight and metabolic rate
GLP1 + Cagrilintide Research Administration Common Study Populations Clinical trials have enrolled diverse participant groups: Adults with obesity BMI 30 kg/m squared or greater without diabetes (REDEFINE 1) Adults with overweight and comorbidities BMI 27 kg/m squared or greater with at least one weight-related condition Adults with type 2 diabetes BMI 27 kg/m squared or greater with established diabetes (REDEFINE 2) Age range Primarily adults aged 18-75 years across trials Geographic diversity Multi-national trials across North America, Europe, Asia, and other regions Exclusion criteria typically included type 1 diabetes, recent cardiovascular events, severe renal or hepatic impairment, history of pancreatitis, and medications causing significant weight changes
Thats not the case with an injection
The US prefers Population Bioequivalence (PBE) and Europe prefers Average Bioequivalence (ABE)
Gastrointestinal Problems Some people have reported nausea, bloating, and abdominal pain after taking huge doses of glutathione